Nanoscale drug delivery systems emerged during the COVID-19 pandemic to overcome severe pharmacological barriers that standard therapeutic agents routinely face in the human body.
A scientific review published in Biomedical Materials Science by Hussein Elaibi and colleagues evaluates how these advanced platforms attempt to improve tissue targeting and drug stability.
Clinical success depends heavily on a drug’s ability to reach target biological tissues at the required time and therapeutic concentration. Conventional therapies struggled throughout the health crisis with poor water solubility, chemical vulnerability, swift elimination from the body, limited ability to penetrate cells, and harmful side effects impacting healthy host cells.
Nanocarriers were designed to resolve these formulation constraints across diverse medical modalities.
Preclinical and early clinical data confirm that these delivery systems can augment local drug exposure and control release kinetics. However, the study authors emphasize that definitive clinical efficacy trials in actual patient populations remain scarce.
Targeting Viral Replication Stages
The review maps therapeutic strategies across distinct intervention stages within the viral replication cycle, including entry inhibition, replication suppression, immunomodulation, and complication management. Entry inhibitors block spike glycoprotein receptor binding or membrane fusion. This specific mechanism remains acutely vulnerable to viral evolution and antigenic drift as mutations diminish target receptor affinity.
Conversely, replication and transcription inhibitors target conserved intracellular machinery such as proteases and RNA proteases, making them more resistant to viral mutations. For these internal agents, achieving adequate tissue concentrations during early disease represents the primary clinical bottleneck.
Pulmonary nanocarriers provide a scientifically justifiable method to enhance local airway exposure while limiting systemic toxicity. Meanwhile, immunomodulatory and complication management strategies require strict phase specificity to prevent premature immunosuppression.
Delivery requirements differ for small molecules and nucleic acids
Delivery requirements diverge significantly across small molecules, biologics, nucleic acids, and combination regimens. Small-molecule compounds are straightforward to synthesize, but their clinical utility is frequently constrained by poor aqueous solubility and rapid clearance. Remdesivir exhibits poor water solubility during standard intravenous delivery, which prompted the development of inhalable lipid or polymeric nanoparticles.
Biological therapies face physical instability and cold-chain dependency. Nucleic acid therapeutics, including small interfering RNA and messenger RNA, present even steeper pharmacological barriers because they are vulnerable to nuclease degradation and cannot traverse anionic cell membranes independently.
Lipid-based delivery vehicles represent one of the most prominent nanocarrier families evaluated for COVID-19. Liposomes feature vesicular phospholipid bilayers enclosing an aqueous core, though they remain susceptible to payload leakage and vesicle aggregation.
Solid lipid nanoparticles incorporate a solid crystalline lipid matrix to facilitate sustained drug release. Nanostructured lipid carriers blend solid lipids with liquid lipids to create an imperfect matrix that enhances payload loading and prevents expulsion during shelf life.
Overcoming Airway and Mucosal Barriers
Given that SARS-CoV-2 exhibits primary tropism for the respiratory tract, lung-targeted delivery receives substantial investigative focus. Direct pulmonary administration through nebulizers or dry powder inhalers delivers therapeutics straight into airways and alveoli.
Aerosol particles possessing aerodynamic diameters between one and five micrometers achieve deep-lung deposition.
Dry powder inhaler formulations must maintain a fine particle fraction to ensure clinical efficacy.
Delivered nanocarriers must overcome the viscoelastic airway mucus layer primarily composed of MUC5AC and MUC5B mucin glycoproteins. Strong electrostatic interactions cause rapid entrapment and mucociliary clearance toward the pharynx unless formulations are engineered as mucus-penetrating systems.
Frequently Asked Questions
What specific pharmacological barriers did COVID-19 drugs encounter?
Traditional medications faced significant obstacles involving poor water solubility, a lack of structural stability, fast elimination by the body, difficulty getting inside cells, and adverse effects on healthy tissues.
Why are nucleic acid therapeutics dependent on nanocarriers?
Messenger RNA and small interfering RNA are highly vulnerable to nuclease degradation and cannot independently traverse anionic cell membranes, making nanocarrier encapsulation an absolute functional necessity.
How do nanostructured lipid carriers improve upon solid lipid nanoparticles?
Nanostructured lipid carriers blend solid lipids with spatially incompatible liquid lipids, creating an imperfect matrix that enhances payload loading and prevents drug expulsion during shelf life.
Related reading